IBB vs VCIT
iShares Biotechnology ETF vs Vanguard Intermediate-Term Corporate Bond ETF
IBB$170.10
iShares Biotechnology ETF
NASDAQ biotech and pharmaceutical companies.
Expense: 0.44%Yield: 0.23%
VCIT$82.60
Vanguard Intermediate-Term Corporate Bond ETF
Intermediate-term investment-grade corporate bonds.
Expense: 0.03%Yield: 4.74%
Quick take
- • VCIT has the lower expense ratio at 0.03% vs 0.44% for IBB.
- • VCIT pays a higher dividend yield (4.74%).
Side-by-side metrics
| Metric | IBB | VCIT |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.44% | 0.03% |
Dividend yield Trailing 12-month yield. | 0.23% | 4.74% |
AUM Assets under management — bigger funds are typically more liquid. | $7.95B | $68.10B |
YTD return | 3.10% | 0.51% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.74 | 1.07 |
P/E ratio | 23.72 | — |
Last price | $170.10 | $82.60 |
Inception | — | — |
Issuer | iShares | Vanguard |
IBB top holdings
Top holdings · IBB
| AMGN | Amgen Inc | 7.37% |
| GILD | Gilead Sciences Inc | 7.32% |
| VRTX | Vertex Pharmaceuticals Inc | 7.21% |
| REGN | Regeneron Pharmaceuticals Inc | 6.55% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.71% |
| ARGX | argenx SE ADR | 3.33% |
| INSM | Insmed Inc | 2.70% |
| BIIB | Biogen Inc | 2.67% |
| NTRA | Natera Inc | 2.40% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.27% |
Sector breakdown · IBB
Healthcare100.0%
VCIT top holdings
Holdings data unavailable for VCIT.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About VCIT
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) is Intermediate-term investment-grade corporate bonds. Managed by Vanguard, the fund carries $68.1B in assets under management, an expense ratio of 0.03%, a dividend yield of 4.74%.